VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

Jamie Koprivnikar, MD
Published: Wednesday, Jan 31, 2018



Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

FLT3 inhibitors are often associated with acute myeloid leukemia (AML), but they are being looked at in other hematologic malignancies as well. A phase II trial looked at untreated patients over the age of 60 who had FLT3-mutated ITD-positive myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), or AML. This trial looked at quizartinib in combination with either azacitidine (Vidaza) or low-dose cytarabine. Promising responses were observed in patients who were previously untreated, with 11 out of 12 patients responding. Overall survival in this population was 18.6 months.

Interestingly, in the previously treated cohort, 5 patients had seen prior exposure to FLT3 inhibitors. This did not affect response, Koprivnikar explained, as 4 out of 5 (80%) of these patients still responded to the combination with quizartinib. An overall response rate of 68% was observed in this previously-treated population, with a median overall survival of 11.2 months.

Finding the optimal FLT3 inhibitor for each particular subgroup will be a continuing area of investigation, says Koprivnikar, as these agents are showing improvements in outcome.


Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

FLT3 inhibitors are often associated with acute myeloid leukemia (AML), but they are being looked at in other hematologic malignancies as well. A phase II trial looked at untreated patients over the age of 60 who had FLT3-mutated ITD-positive myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML), or AML. This trial looked at quizartinib in combination with either azacitidine (Vidaza) or low-dose cytarabine. Promising responses were observed in patients who were previously untreated, with 11 out of 12 patients responding. Overall survival in this population was 18.6 months.

Interestingly, in the previously treated cohort, 5 patients had seen prior exposure to FLT3 inhibitors. This did not affect response, Koprivnikar explained, as 4 out of 5 (80%) of these patients still responded to the combination with quizartinib. An overall response rate of 68% was observed in this previously-treated population, with a median overall survival of 11.2 months.

Finding the optimal FLT3 inhibitor for each particular subgroup will be a continuing area of investigation, says Koprivnikar, as these agents are showing improvements in outcome.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x